MCID: MNT002
MIFTS: 51

Mental Depression

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression 11 5 14 71
Depressive Disorder 71
Depression 43

Classifications:



External Ids:

Disease Ontology 11 DOID:1596
MeSH 43 D003863
NCIt 49 C2982
SNOMED-CT 68 41006004
ICD10 31 F33.9
UMLS 71 C0011570 C0011581

Summaries for Mental Depression

MalaCards based summary: Mental Depression, also known as depressive disorder, is related to postpartum depression and bipolar disorder, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Signal Transduction and Interleukin-4 and Interleukin-13 signaling. The drugs Propofol and Trimipramine have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and breast, and related phenotypes are nervous system and behavior/neurological

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2476)
# Related Disease Score Top Affiliating Genes
1 postpartum depression 33.2 SLC6A4 POMC OXT MAOA IL6 HTR2A
2 bipolar disorder 33.1 SLC6A4 PRODH MIR132 MAOA IL6 HTR2A
3 anxiety 32.8 SLC6A4 PRODH POMC OXT MAOA IL6
4 atypical depressive disorder 32.7 SLC6A4 SERPINA3 POMC MAOA IL6 HTR2A
5 dysthymic disorder 32.5 SLC6A4 PRODH POMC OXT MAOA IL6
6 major depressive disorder 32.4 TWNK SLC6A4 POMC OXT NOTCH3 MAOA
7 headache 32.4 SLC6A4 HTR2A BDNF
8 bipolar i disorder 32.3 SLC6A4 PRODH HTR2A HTR1A BDNF
9 alcohol use disorder 32.3 SLC6A4 SERPINA3 PRODH POMC MAOA IL6
10 fibromyalgia 32.3 SLC6A4 POMC OXT MAOA IL6 HTR2A
11 eating disorder 32.3 SLC6A4 POMC OXT HTR2A HTR1A H2AC18
12 schizoaffective disorder 32.3 SLC6A4 SERPINA3 PRODH HTR2A HTR1A BDNF
13 dementia 32.3 SERPINA3 NOTCH3 MAOA IL6 HTR2A HTR1A
14 personality disorder 32.2 SLC6A4 MAOA HTR2A HTR1A CRH BDNF
15 parkinson disease, late-onset 32.2 SLC6A4 SERPINA3 PRODH MIRLET7D MIR132 MIR124-1
16 dementia, lewy body 32.2 SERPINA3 MIRLET7D MIR132 H2AC18 BDNF
17 sleep apnea 32.2 SLC6A4 IL6 HTR2A BDNF
18 bulimia nervosa 32.1 SLC6A4 OXT MAOA HTR2A BDNF
19 borderline personality disorder 32.1 SLC6A4 MAOA HTR2A HTR1A CRH BDNF
20 gilles de la tourette syndrome 32.1 SLC6A4 MAOA HTR2A HTR1A BDNF
21 apnea, obstructive sleep 32.1 POMC MIRLET7D IL6 HTR2A BDNF
22 migraine with or without aura 1 32.1 SLC6A4 SERPINA3 POMC OXT NOTCH3 MAOA
23 supranuclear palsy, progressive, 1 32.0 SERPINA3 MIR132 DCTN1
24 obsessive-compulsive disorder 32.0 SLC6A4 POMC OXT MAOA IL6 HTR2A
25 cyclothymic disorder 32.0 SLC6A4 HTR2A HTR1A BDNF
26 post-traumatic stress disorder 32.0 SLC6A4 POMC OXT MIR124-1 MAOA IL6
27 huntington disease 32.0 SERPINA3 PRODH MIR132 MAOA H2AC18 BDNF
28 type 2 diabetes mellitus 32.0 SERPINA3 PRODH POMC MIRLET7D IL6 HTR2A
29 schizophrenia 32.0 SLC6A4 SERPINA3 PRODH POMC OXT MIR132
30 interstitial cystitis 32.0 IL6 CRH BDNF
31 autism spectrum disorder 32.0 SLC6A4 PRODH OXT MIR598 MIR132 MAOA
32 panic disorder 32.0 SLC6A4 POMC MAOA IL6 HTR2A HTR1A
33 stroke, ischemic 31.9 SERPINA3 NOTCH3 MIR124-1 IL6 BDNF
34 acne 31.9 POMC IL6 CRH
35 cerebrovascular disease 31.9 SERPINA3 NOTCH3 MIR132 MIR124-1 IL6 H2AC18
36 endogenous depression 31.9 SLC6A4 POMC OXT MAOA IL6 HTR2A
37 binswanger's disease 31.9 NOTCH3 CRH
38 acute stress disorder 31.9 SLC6A4 POMC OXT HTR2A CRH BDNF
39 generalized anxiety disorder 31.9 SLC6A4 PRODH POMC OXT MAOA IL6
40 adult syndrome 31.8 POMC IL6 H2AC18 CRH
41 alcohol dependence 31.8 SLC6A4 SERPINA3 POMC MAOA HTR2A HTR1A
42 conversion disorder 31.8 HTR2A BDNF
43 pulmonary disease, chronic obstructive 31.8 SERPINA3 MIRLET7D IL6 H2AC18
44 mild cognitive impairment 31.8 SERPINA3 MIRLET7D MIR132 IL6 BDNF
45 psychotic disorder 31.8 SLC6A4 SERPINA3 PRODH OXT MIRLET7D MIR598
46 diabetes mellitus 31.7 SERPINA3 POMC OXT MIR132 IL6 CRH
47 epilepsy 31.7 PRODH POMC MIR132 MIR124-1 MAOA IL6
48 melancholia 31.7 SLC6A4 POMC OXT MAOA IL6 HTR2A
49 asperger syndrome 31.7 SLC6A4 OXT BDNF
50 alexithymia 31.7 SLC6A4 OXT HTR2A H2AC18 CRH BDNF

Graphical network of the top 20 diseases related to Mental Depression:



Diseases related to Mental Depression

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:


dejection emotional; depressed reaction; depression aggravated; affective symptoms; behavioral symptoms; schizophrenic language; depressive symptoms; depressed - symptom

MGI Mouse Phenotypes related to Mental Depression:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.77 BDNF CRH DCTN1 HTR1A IL6 MAOA
2 behavior/neurological MP:0005386 9.5 BDNF CRH DCTN1 HTR1A HTR2A IL6

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 768)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
2
Trimipramine Approved Phase 4 739-71-9 5584
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
5
Copper Approved, Investigational Phase 4 7440-50-8 27099
6
Norethisterone Approved Phase 4 68-22-4 199472 6230
7
Lactulose Approved Phase 4 4618-18-2 11333
8
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
9
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
10
Isocarboxazid Approved Phase 4 59-63-2 3759
11
Protriptyline Approved Phase 4 438-60-8 4976
12
Desipramine Approved, Investigational Phase 4 50-47-5 2995
13
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
14
Rasagiline Approved Phase 4 136236-51-6 3052776
15
Ribavirin Approved Phase 4 36791-04-5 37542
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
18
Cycloserine Approved Phase 4 68-41-7 6234
19
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
20
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
21
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
22
Calcium carbonate Approved, Investigational Phase 4 471-34-1
23
Nefazodone Approved, Withdrawn Phase 4 82752-99-6, 83366-66-9 4449
24
Haloperidol Approved Phase 4 52-86-8 3559
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
26
Ropinirole Approved, Investigational Phase 4 91374-21-9 5095
27
Iloperidone Approved Phase 4 133454-47-4 71360
28
Losartan Approved Phase 4 114798-26-4 3961
29
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
30
Zolpidem Approved Phase 4 82626-48-0 5732
31
Raloxifene Approved, Investigational Phase 4 82640-04-8, 84449-90-1 5035
32
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
33
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
34
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
35
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
36
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
37
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
38
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181
39
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
40
Benzatropine Approved Phase 4 86-13-5 1201549
41
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
42
Doxylamine Approved, Vet_approved Phase 4 562-10-7, 469-21-6 3162
43
Rilpivirine Approved Phase 4 500287-72-9 6451164
44
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
45
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537 59227
46
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
47
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
48
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
49
Coal tar Approved Phase 4 8007-45-2
50
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643

Interventional clinical trials:

(show top 50) (show all 7988)
# Name Status NCT ID Phase Drugs
1 Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder Unknown status NCT02752542 Phase 4 Pharmacotherapy
2 International Study to Predict Optimised Treatment - in Depression Unknown status NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
3 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
4 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
5 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
6 Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR) Unknown status NCT02711215 Phase 4 Citalopram;Escitalopram (Mirtazapine/Duloxetine/Venlafaxine);Placebo
7 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
8 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
9 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
10 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
11 Ketamine Enhancement of rTMS for Refractory Depression Unknown status NCT04352621 Phase 4 intranasal ketamine
12 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
13 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Unknown status NCT03881449 Phase 4
14 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
15 A Prospective Post Marketing Surveillance Study Study for the Evaluation of the Safety and Efficacy of the Predictix Antidepressant (PAD) Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder Unknown status NCT04138290 Phase 4
16 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
17 Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy Unknown status NCT03187093 Phase 4 Vortioxetine;Escitalopram
18 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
19 Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics Unknown status NCT03219008 Phase 4 Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
20 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
21 Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial Unknown status NCT03666494 Phase 4 Ketamine Hydrochloride;Propofol;Fentanyl
22 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
23 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
24 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
25 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
26 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
27 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
28 Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
29 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
30 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Bupropion;Trazodone
31 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
32 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
33 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
34 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
35 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
36 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
37 A Prospective, Single-Blinded, Randomized, Multicentre Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform the Prescription of Medications to Subjects With a Primary Diagnosis of a Depressive Disorder Unknown status NCT04620499 Phase 4
38 Agomelatine Added to SSRIs or SNRIs for Early-nonresponsive Patients With Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT04589143 Phase 4 Agomelatine;Placebos
39 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
40 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
41 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
42 Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression Unknown status NCT04234776 Phase 4 Ketamine
43 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
44 Objective to Evaluate the Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Depressive Episode: a Multicenter Open Randomized Controlled Clinical Trial Unknown status NCT04826510 Phase 4 Perospirone hydrochloride tablets;Lithium carbonate + perospirone hydrochloride;Lithium Carbonate Pill
45 Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. Unknown status NCT03491696 Phase 4 Metyrapone
46 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
47 The Assessment of Osteoporosis Treatment in Post-menopausal Women Unknown status NCT03006003 Phase 4 Raloxifene;Alendronate
48 Randomized Trial Evaluating the Effectiveness of MYnd Analytics Directed Therapy in Depression Unknown status NCT03328052 Phase 4
49 A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
50 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: depression

Genetic Tests for Mental Depression

Anatomical Context for Mental Depression

Organs/tissues related to Mental Depression:

MalaCards : Brain, Prefrontal Cortex, Breast, Heart, Temporal Lobe, Spinal Cord, Cortex

Publications for Mental Depression

Articles related to Mental Depression:

(show top 50) (show all 307)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
2
Loss of Nardilysin, a Mitochondrial Co-chaperone for α-Ketoglutarate Dehydrogenase, Promotes mTORC1 Activation and Neurodegeneration. 5
28017472 2017
3
A network pharmacology approach to predict potential targets and mechanisms of "Ramulus Cinnamomi (cassiae) - Paeonia lactiflora" herb pair in the treatment of chronic pain with comorbid anxiety and depression. 62
35098831 2022
4
Exercise facilitates regeneration after severe nerve transection and further modulates neural plasticity. 62
36405423 2022
5
The Structural Relationship on Nostalgia Recognition Effect, Attachment, Resilience, and Psychological Well-Being of Dance for All Participants during the COVID-19 Pandemic. 62
36141405 2022
6
Berberine: is a Promising Agent for Mental Disorders Treatment? 62
35538795 2022
7
[Establishment and comparison of three human multiple myeloma cell line transplantation models in mice]. 62
35680600 2022
8
Influence of dental magnets on human brain activity: A quantitative EEG analysis. 62
34553779 2022
9
Outcomes of upper gastrointestinal cancer screening in high-risk individuals: a population-based prospective study in Northeast China. 62
35168959 2022
10
Herbal Approaches in the Management of Mental Depression. 62
35088681 2022
11
Analysis and Research on the Rehabilitation Effect of Physical Exercise on College Students' Mental Depression Based on Multidimensional Data Mining. 62
35912309 2022
12
Empirical Investigation for Predicting Depression from Different Machine Learning Based Voice Recognition Techniques. 62
35432567 2022
13
A Review on the Neuroprotective Effect of Berberine against Chemotherapy- induced Cognitive Impairment. 62
35240956 2022
14
Dezocine Has the Potential to Regulate the Clinical and Biological Features of Tumors. 62
35478934 2022
15
Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (Review). 62
34633054 2021
16
The Relationship Between Neighborhood Deprivation and Perceived Changes for Pain-Related Experiences Among US Patients with Chronic Low Back Pain During the COVID-19 Pandemic. 62
34181008 2021
17
Questionnaire-based Survey of Demographic and Clinical Characteristics, Health Behaviors, and Mental Health of Young Korean Adults with Early-onset Diabetes. 62
34227263 2021
18
The burden of mental disorders in Mexico, 1990-2019: Mental and neurological disorders, substance use, suicides, and related somatic disorders. 62
34246817 2021
19
Neural Network Based Mental Depression Identification and Sentiments Classification Technique From Speech Signals: A COVID-19 Focused Pandemic Study. 62
34938711 2021
20
Anxiety, Anger and Depression Amongst Low-Income Earners in Southwestern Uganda During the COVID-19 Total Lockdown. 62
34956994 2021
21
Antidepressant Mechanism of Traditional Chinese Medicine Formula Xiaoyaosan in CUMS-Induced Depressed Mouse Model via RIPK1-RIPK3-MLKL Mediated Necroptosis Based on Network Pharmacology Analysis. 62
34867405 2021
22
The importance of and satisfaction with sex life among breast cancer survivors in comparison with healthy female controls and women with mental depression or arterial hypertension: results from the Finnish nationwide HeSSup cohort study. 62
31836939 2020
23
Ethnopharmacology of Hypericum species in China: A comprehensive review on ethnobotany, phytochemistry and pharmacology. 62
32101776 2020
24
Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series. 62
32251268 2020
25
Effect of antidepressants on various periodontal parameters: A case-control study. 62
32189839 2020
26
Overview of dropped head syndrome (Combined survey report of three facilities). 62
31444010 2019
27
[Exploration of modern scientific connotation of Miao medicine Qizu Xueyu syndrome and intervention mechanism of Kangfuyan Capsules]. 62
31872611 2019
28
Recovery of chicken growth plate by TanshinoneⅡA through wnt/β-catenin pathway in thiram-induced Tibial Dyschondroplasia. 62
31442808 2019
29
Fecal microbiota transplantation in an elderly patient with mental depression. 62
30782238 2019
30
Persistent pit viper envenomation in three dogs. 62
31129161 2019
31
The Effect of Interventional Pain Management on Treating Postherpetic Neuralgia. 62
31148876 2019
32
Aesthetic abdominoplasty has a positive impact on quality of life prospectively. 62
30638894 2019
33
Stress and perceived social isolation (loneliness). 62
30825769 2019
34
The Mental Health of Young Canadians Who Are Not Working or in School. 62
30595044 2019
35
Overexpression of microRNA-301b accelerates hippocampal microglia activation and cognitive impairment in mice with depressive-like behavior through the NF-κB signaling pathway. 62
30962417 2019
36
The emergence of a highly pathogenic porcine reproductive and respiratory syndrome virus with additional 120aa deletion in Nsp2 region in Jiangxi, China. 62
30024111 2018
37
[Diagnosis and treatment of intra-abdominal infection complicated with hypothyroidism]. 62
30588585 2018
38
Atrophic and Annular Scarring Alopecia of the Scalp as a Finding in Underlying Systemic Sarcoidosis. 62
30064604 2017
39
Social support and breast cancer: A comparatory study of breast cancer survivors, women with mental depression, women with hypertension and healthy female controls. 62
28667868 2017
40
Dimorphic anemia and mental depression as a result of systemic manifestations of generalized aggressive periodontitis: A pioneer case report. 62
29491590 2017
41
[Psoriasis and erectile dysfunction: An update]. 62
28965388 2016
42
Client satisfaction: correlates and implications for improving HIV/AIDS treatment and care services in southern Ethiopia. 62
27008895 2016
43
Desipramine improves depression-like behavior and working memory by up-regulating p-CREB in Alzheimer's disease associated mice. 62
27338163 2016
44
Fecal microbiota transplantation for recurrent Clostridium difficile infection: The patient experience. 62
26944009 2016
45
Support for the hypothesis that sexual breast stimulation is an ancestral practice and a key to understanding women's health. 62
26386486 2015
46
Correlates of Mental Depression Among Female Sex Workers in Southern India. 62
26307144 2015
47
Evaluation of the antidepressant activity of Moringa oleifera alone and in combination with fluoxetine. 62
26834427 2015
48
Optimizing the compatibility of paired-herb in an ancient Chinese herbal decoction Kai-Xin-San in activating neurofilament expression in cultured PC12 cells. 62
25560671 2015
49
Monetizing illness: the influence of disability assistance priming on how we evaluate the health symptoms of others. 62
25577289 2015
50
Risk factors for late-onset generalized anxiety disorder: results from a 12-year prospective cohort (the ESPRIT study). 62
25826111 2015

Variations for Mental Depression

ClinVar genetic disease variations for Mental Depression:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 OGDHL NM_018245.3(OGDHL):c.2174A>T (p.Asn725Ile) SNV Affects
1292053 GRCh37: 10:50947852-50947852
GRCh38: 10:49739806-49739806
2 NOTCH3 NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg) SNV Pathogenic
812745 rs1555729455 GRCh37: 19:15302816-15302816
GRCh38: 19:15192005-15192005
3 TWNK NM_021830.5(TWNK):c.1121G>A (p.Arg374Gln) SNV Likely Pathogenic
426106 rs1554887097 GRCh37: 10:102749088-102749088
GRCh38: 10:100989331-100989331
4 NOTCH3 NM_000435.3(NOTCH3):c.1136G>C (p.Cys379Ser) SNV Likely Pathogenic
812744 rs1599391986 GRCh37: 19:15300140-15300140
GRCh38: 19:15189329-15189329
5 MRE11 NM_005591.4(MRE11):c.229G>A (p.Glu77Lys) SNV Uncertain Significance
481777 rs779269083 GRCh37: 11:94219175-94219175
GRCh38: 11:94486009-94486009
6 MRE11 NM_005591.4(MRE11):c.1727G>A (p.Arg576Gln) SNV Uncertain Significance
127974 rs139461096 GRCh37: 11:94180441-94180441
GRCh38: 11:94447275-94447275

Expression for Mental Depression

Search GEO for disease gene expression data for Mental Depression.

Pathways for Mental Depression

GO Terms for Mental Depression

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin receptor signaling pathway GO:0007210 9.46 HTR2A HTR1A
2 behavior GO:0007610 9.26 HTR2A HTR1A
3 sperm ejaculation GO:0042713 9.26 SLC6A4 OXT
4 memory GO:0007613 9.23 SLC6A4 OXT HTR2A BDNF

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.1 SLC6A4 HTR2A HTR1A

Sources for Mental Depression

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....